Isavuconazole Therapeutic Drug Monitoring during Long-Term Treatment for Chronic Pulmonary Aspergillosis
Chris Kosmidis, Akan Otu, Caroline B. Moore, Malcolm Richardson, Riina Rautemaa‐Richardson
Abstract
Isavuconazole is the newest triazole antifungal, and it displays a favorable pharmacokinetic and safety profile. Less is known about its long-term use in immunocompetent hosts. We performed a retrospective service evaluation of isavuconazole therapeutic drug monitoring in patients with chronic pulmonary aspergillosis. Adverse events (AEs) and dose adjustments made during routine clinical practice were recorded, and AEs were classified based on Common Terminology Criteria for Adverse Events v5.0.
Topics & Concepts
MedicineAspergillosisAdverse effectCommon Terminology Criteria for Adverse EventsIntensive care medicineDrugTherapeutic drug monitoringPulmonary aspergillosisPharmacokineticsVoriconazoleAntifungalInternal medicinePharmacologyDermatologyImmunologyAntifungal resistance and susceptibilityFungal Infections and StudiesPneumocystis jirovecii pneumonia detection and treatment